FYF: Face Your Fears: Cognitive Behavioural Virtual Reality Therapy for "Paranoia".

Sponsor
Mental Health Services in the Capital Region, Denmark (Other)
Overall Status
Recruiting
CT.gov ID
NCT04902066
Collaborator
Central Denmark Region (Other), Mental Health Services in the North Denmark Region (Other)
256
1
2
38.7
6.6

Study Details

Study Description

Brief Summary

The study is a randomised, assessor-blinded parallel-groups superiority clinical trial fulfilling the CONSORT criteria for non-pharmacological treatment. A total of 256 patients will be allocated to either Cognitive Behavioural Virtual Reality Therapy plus treatment as usual, versus traditional CBT for psychosis plus treatment as usual. All participants will be assessed at baseline and 3- and 9 months post baseline. A stratified block-randomisation with concealed randomisation sequence will be conducted. Independent assessors blinded to the treatment will evaluate outcome. Analysis of outcome will be carried out with the intention to treat principles.

Condition or Disease Intervention/Treatment Phase
  • Other: Cognitive Behavioural Virtual Reality Therapy.
  • Other: Traditional Cognitive Behavioural Therapy
N/A

Detailed Description

Ideas of reference and ideas of persecution are among the most frequent symptoms in psychotic disorders, and they hinder patients in conducting daily activities such as leaving the home or using public transportation - as well as inflicting immensely on their quality of life. The social avoidance caused by these symptoms does not improve with antipsychotic mediation. Cognitive behavioural therapy (CBT) for psychosis has demonstrated beneficial effect on psychotic symptoms, but the average effect sizes are in the small to moderate range, and training and resource requirements mean that, in practice, therapy is not delivered to all those who might benefit. Hence, there is considerable interest in the development of novel therapies that draw on the principles of cognitive behavioural therapy for psychosis, but which are shorter, more effective, and are capable of being delivered by a wider workforce. Augmenting CBT with virtual reality exposure has the possibility of creating artificial experiences in real time, that make the user feel immersed and able to interact as if it was the real world. Additionally, virtual reality therapy allows for personalization of the therapy to match the specific social challenges of each patient. Preliminary findings suggest virtual reality exposure to lead to faster symptom reduction than traditional therapy. While the potential beneficial effects of virtual reality exposure to psychotic, and sub-threshold psychotic symptoms, such as ideas of reference and ideas of persecution, are evident and virtual reality therapies are promising in general, the research field is in an urgent need of evidence on the effectiveness of virtual reality therapy in patients with schizophrenia spectrum disorders. The proposed trial is hitherto the largest trial in the world to evaluate the effectiveness of cognitive behavioural virtual reality therapy (CBT-VR) compared to traditional CBT. The investigators expect to find CBT-VR to be more beneficial in reducing ideas of reference and ideas of persecution in patients with schizophrenia spectrum disorders. Additionally, the investigators expect it to result in improved depressive, anxiety-, and negative symptoms, as well as improved social cognition and psychosocial functioning and quality of life in patients with schizophrenia spectrum disorders. The target group in the trial also encompass patients with schizotypal disorder (often young adults), showing subthreshold psychotic symptoms (e.g. ideas of reference), that are at increased risk of developing manifest psychosis. The CBT-VR may show efficacy in preventing progression to an overt psychotic state in these patients. Hence, there is a great potential for CBT-VR in the treatment of patients with psychosis and sub-threshold psychosis, but studies are needed to establish evidence for the treatment. If the results of the current trial are positive, the manualised treatment can easily be implemented in clinical practise.

Note: As of February 23 (10 months into the study), we changed our primary outcome, GPTS B, ideas of persecution, with our secondary outcome, GPTS A, ideas of reference, as we realized, that our population primarily are affected by ideas of reference and to a lesser extent ideas of persecution. This is possible due to our inclusion criteria, which is a GPTS totalscore of ideas of reference and ideas of persecution above 40 (minimumscore is 32). Some patients therefore display a score in ideas of persecution that are below threshold for relevant clinical change (6.0) in this study.

Ideas og reference and ideas of persecution are two sides of the same coin from a psychopathological point of view. Often with ideas of reference being present on its own in milder cases, and in increasing symptom severity, ideas of persecution being added.

No statistical calculations have been made at this point. 79 participants out of 265 are included and have participated in baseline assessments.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
256 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
A randomised, assessor-blinded parallel-groups superiority clinical trial.A randomised, assessor-blinded parallel-groups superiority clinical trial.
Masking:
Single (Outcomes Assessor)
Masking Description:
Independent assessors blinded to the treatment will evaluate outcome.
Primary Purpose:
Treatment
Official Title:
Face Your Fears: An Assessor-blinded, RCT Evaluating the Effectiveness of Cognitive Behavioural Virtual Reality Therapy Versus Cognitive Behavioural Therapy in Patients With Schizophrenia Spectrum Disorders.
Actual Study Start Date :
Apr 9, 2021
Anticipated Primary Completion Date :
Oct 1, 2023
Anticipated Study Completion Date :
Jul 1, 2024

Arms and Interventions

Arm Intervention/Treatment
Experimental: Cognitive Behavioural Virtual Reality Therapy (CBT-VR)

The CBT-VR consists of traditional CBT with the augmentation of virtual reality exposure. The virtual reality exposure comprises four virtual social environments (a bus, café, street, and supermarket). These are daily social situations that generally elicit paranoid thinking in patients with a schizophrenia spectrum disorder. While virtually engaging in these distressing situations, the therapist will facilitate a CBT dialogue aimed at generating alternative (i.e. non-threatening) thinking, diminishing safety behaviours (e.g. social isolation), and building up new coping strategies. This is expected to alleviate distress, anxiety, and improve daily social functioning. Preliminary findings reveal this virtual reality program to be well-tolerated and highly effective in reducing paranoia and anxiety in psychosis. Patients will be offered 10 individual sessions.

Other: Cognitive Behavioural Virtual Reality Therapy.
Cognitive Behavioural Therapy augmented with Virtual Reality.

Active Comparator: Traditional Cognitive Behavioural Therapy

The treatment in the CBT group will follow the core principles of CBT used for psychotic disorders. The CBT treatment facilitates an individualised, problem-oriented approach, and uses key CBT techniques such as developing a problem and goal list, normalising psychotic-like experiences, evaluation of appraisals, and removing or diminishing safety behaviour. Patients will be offered 10 individual sessions.

Other: Traditional Cognitive Behavioural Therapy
Traditional Cognitive Behavioural Therapy for psychosis.

Outcome Measures

Primary Outcome Measures

  1. (GPTS) Green Paranoid Thought Scale Part A: Ideas of reference. [3 months from inclusion]

    The primary outcome is level of ideas of reference measured with Green Paranoid Thought Scale at cessation of treatment at 3-months. The Green Paranoid Thought Scale has displayed good reliability and validity in patients with psychosis, displaying paranoid, persecutory delusions, and has also been used in patients at-risk for psychosis showing subthreshold psychotic symptoms. Minimum total score: 32. Maximum total score: 160. Part A (Ideas of reference) minimum score: 16 and maximum score: 80. Part B (ideas of persecution) minimum score 16 and maximum score: 80. Part B score = or > 45 are assumed to be threshold for development of persecutory delusion. Higher score means worse outcome.

Secondary Outcome Measures

  1. SIAS (Social Interaction Anxiety Scale) [3 and 9 months from inclusion]

    Minimum score: 0 Maximum score: 20*4=80. Item 5,9 and 11 have reverse score. Higher score means worse outcome.

  2. SBQ (Safety Behaviour Questionnaire) [3 and 9 months from inclusion]

    Minimum score: 0. Maximum score is in theory unlimited depending on the number of identified, specific safety behaviours.

  3. PSP (Personal and Social Performance Scale) [3 and 9 months from inclusion]

    Minimum score: 1 Maximum score: 100. Higher score means better outcome.

  4. CANTAB ERT (Emotion Recognition Task) [3 and 9 months from inclusion]

  5. (GPTS) Green Paranoid Thought Scale Part B: Ideas of persecution [3 and 9 months from inclusion]

    Minimum total score: 32. Maximum total score: 160. Part A (Ideas of reference) minimum score: 16 and maximum score: 80. Part B (Ideas of persecution) minimum score 16 and maximum score: 80. Part B score = or > 45 are assumed to be threshold for development of delusion. Higher score means worse outcome.

  6. (GPTS) Green Paranoid Thought Scale Part A: Ideas of reference [9 months from inclusion]

    The primary outcome is level of ideas of reference measured with Green Paranoid Thought Scale at cessation of treatment at 3-months. The Green Paranoid Thought Scale has displayed good reliability and validity in patients with psychosis, displaying paranoid, persecutory delusions, and has also been used in patients at-risk for psychosis showing subthreshold psychotic symptoms. Minimum total score: 32. Maximum total score: 160. Part A (Ideas of reference) minimum score: 16 and maximum score: 80. Part B (Ideas of persecution) minimum score 16 and maximum score: 80. Part B score = or > 45 are assumed to be threshold for development of delusion. Higher score means worse outcome.

Other Outcome Measures

  1. CDSS (Calgary Depression Scale for Schizophrenia) [3 and 9 months from inclusion]

    Minimum score: 0 Maximum score: 9*3 = 27. Higher score means worse outcome.

  2. BNSS (Brief Negative Symptom Scale) [3 and 9 months from inclusion]

    13 items with a score from minimum 0 to maximum 6 for each item. Higher score means worse outcome.

  3. COGDIS (Cognitive disturbances scale) [3 and 9 months from inclusion]

    Score of 0-6 indicate a range. Minimum score: 0 Maximum score: 9*6 = 54. Higher score means worse outcome. Trait phenomenons are coded with a "7", unknown degree of severly is coded with a "8" and uncertainty whether the symptom is present is coded with a "9".

  4. SAPS (Scale for the Assesment of Positive symptoms) [3 and 9 months from inclusion]

    Composite total score: Minimum score: 0 Maximum score: 30*5 = 150. Higher score means worse outcome. Global score: Minimum score: 0 Maximum score: 4*5 = 20. Higher score means worse outcome.

  5. Trustworthiness Scale [3 and 9 months from inclusion]

    Minimum score: -3*42=-126 Maximun score: +3*42=126. Higher positive score means better outcome. Higher negative score means worse outcome.

  6. DACOBS (Davos Assessment of the Cognitive Biases Scale) [3 and 9 months from inclusion]

    Total score: Minimum score: 1*42=42. Maximum score:7*42=294. Higher score means worse outcome. Subscales of: Jumping to conclusions bias: Item 3+8+16+18+25+30 Belief Inflexibility bias: Item 13+15+26+34+38+41 Attention for Threat bias: Item 1+2+6+10+20+37 External Attribution bias: Item 7+12+17+22+24+29 Social Cognition problems: Item 4+9+11+14+19+39 Subjective Cognitive problems: Item 5+21+28+32+36+40 Safety behaviors: Item 23+27+31+33+35+42

  7. SIDAS (Suicidal Ideation Attributes Scale) [3 and 9 months from inclusion]

    Minimum score: 0. Maximum score: 50. Item 2 has a reverse score. Higher score means worse outcome.

  8. BCSS (The Brief Core Schema Scales: Beliefs about self and others) [3 and 9 months from inclusion]

    Items with negative belief of self and others: Minimum score: 0. Maximum score: 2*6*4= 48. Higher score means worse outcome. Items with Positive belief of self and others: Minimum score: 0. Maximum score: 2*6*4= 48. Higher score means better outcome.

  9. SSPA (Social Skills Performance Assessment) [3 and 9 months from inclusion]

    Scene I: Minimum score: 1*8=8. Maximum score: 5*8:40. Higher score means better outcome. Scene II: Minimum score: 1*9=9. Maximum score: 5*9:45. Higher score means better outcome.

  10. TALE (Trauma And Life Events checklist) [Baseline measure]

  11. IBT (Intentionality Bias Task) [3 and 9 months from inclusion]

  12. (R-GPTS) Revised Green Paranoid Thought Scale [3 and 9 months from inclusion]

    Minimum total score: 0. Maximum total score: 4*18=72. Part A (Ideas of reference) minimum score: 0 and maximum score: 4*8=32. Part B (Ideas of persecution) minimum score 0 and maximum score: 4*10=40. Part B score = or > 18 are assumed to be threshold for development of delusion. Higher score means worse outcome.

  13. GSE (General Self Efficacy Scale) [3 and 9 months from inclusion]

    Minimum score: 1*10=10. Maximum score: 4*10=40. Higher score means better outcome.

  14. Big-5 (personality traits) [3 and 9 months from inclusion]

    5 spectrums of personality traits assessed with 5 items each. Minimum score for each personality trait: Minimum score: 1*5=5. Maximum score: 5*5=25 Certain items have reverse scores.

  15. EQ-5D-5L (EuroQOL five dimensions questionnaire) [3 and 9 months from inclusion]

    Scoring the descriptive system: Minimum score: 1-1-1-1-1. Maximum score: 5-5-5-5-5. Higher score means worse outcome. Scoring the VAS: Minimum score: 0. Maximum score: 100. Higher score means better outcome.

  16. WHO (World Health Organization 5) [3 and 9 months from inclusion]

    Minimum score: 0. Maximum score: 5*5*4=100. Higher score means better outcome.

  17. CSQ (Client Satisfaction Questionnaire) [3 months follow-up]

  18. SFS (The Social Functioning Scale) [3 and 9 months from inclusion]

    Minimum raw score: 0. Maximum raw score: 15+9+39+45+66+39+19=223. Higher score means better outcome.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  1. Age 18 - years

  2. Ability to give informed consent

  3. A schizophrenia spectrum disorder (ICD-10 code: F20 -F29)

  4. Green Paranoid Thought Scale total score ≥ 40

Exclusion Criteria:
  1. Rejecting informed consent

  2. A diagnosis of organic brain disease

  3. IQ of 70 or lower (known mental retardation as assessed by medical record)

  4. A command of spoken Danish or English inadequate for engaging in therapy

  5. Inability to tolerate the assessment process

Contacts and Locations

Locations

Site City State Country Postal Code
1 Copenhagen Research Center for Mental Health - CORE Copenhagen Hellerup Denmark 2900

Sponsors and Collaborators

  • Mental Health Services in the Capital Region, Denmark
  • Central Denmark Region
  • Mental Health Services in the North Denmark Region

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Merete Nordentoft, Professor, Mental Health Services in the Capital Region, Denmark
ClinicalTrials.gov Identifier:
NCT04902066
Other Study ID Numbers:
  • 0134-00066B and ID 148727
First Posted:
May 26, 2021
Last Update Posted:
Mar 11, 2022
Last Verified:
Feb 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Mar 11, 2022